Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GenSpera has received US Patent 7,906,47, entitled, 'Activation of Peptide Prodrugs by HK2,' from the US Patent and Trademark Office (USPTO) covering the composition of Ac-GKAFRR-L12ADT to deliver a potent thapsigargin derivative selectively to prostate cancers.
Subscribe to our email newsletter
GenSpera owns and controls all rights to Ac-GKAFRR-L12ADT and anticipates a strategic partnership to maximize the value of the drug as it progresses through future clinical trials.
GenSpera president and CEO Craig Dionne said the issuance of this patent further strengthens their intellectual property position for Ac-GKAFRR-L12ADT and affords recognition of its novel utility in prostate cancer.
"It is important that we continue to expand and defend our thapsigargin prodrug research and development into areas of high unmet medical needs and commercial opportunities," Dionne said.